MRTX - Mirati Therapeutics, Inc.
After hours:
Chart Events
Inside Bar (Bullish)
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 37.01 |
| Open | 37.06 |
| Bid | 39.00 x 1000 |
| Ask | 38.27 x 800 |
| Day's Range | 36.85 - 38.40 |
| 52 Week Range | 35.70 - 101.30 |
| Volume | |
| Avg. Volume | 1,033,896 |
| Market Cap | 2.226B |
| Beta (5Y Monthly) | 1.04 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -12.93 |
| Earnings Date | Aug 01, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 66.33 |
Fair Value
Related Research
PR NewswireMirati Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023 on June 15 at 8:40 a.m. P.T. / 11:40 a.m. E.T. David Meek, chief executive officer, will represent the company in a fireside chat at the conference.
ZacksBiotech Stock Roundup: MRTX Falls on Study Failure, LXRX Drug Wins Approval & More
Regulatory and pipeline updates from Mirati (MRTX) and Lexicon (LXRX) are in focus in the biotech sector.
InvestopediaTop Stocks for June 2023
Southwestern Energy, Mirati Therapeutics, and First Solar are top US stocks Russell 3000 in June 2023 for value, growth, and momentum, respectively.
TipRanksOppenheimer Sees Over 50% Gains in These 2 Stocks — Here’s Why They Could Soar
The shortened week kicked off with one big crisis averted for now. During the long weekend, an agreement was reached between President Biden and House Majority Leader McCarthy that should go toward resolving the debt ceiling. Oppenheimer’s Chief Investment Strategist John Stoltzfus expects a positive reaction to the progress being made to get the deal done. “In our view this portends well for the US and the markets even while it doesn’t eliminate the potential for angst near term as the agreemen
- PR Newswire
Mirati To Encore Compelling Clinical Data Demonstrating Adagrasib's Potential as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors at 2023 ASCO Annual Meeting
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced presentations and posters to be shared at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating the utility of adagrasib across multiple tumor types.
BenzingaMirati's Sitravatinib Flunks Phase 3 Combo Therapy Study In Type Of Lung Cancer Setting
Mirati Therapeutics Inc's (NASDAQ: MRTX) SAPPHIRE study did not meet its primary endpoint of overall survival at the final analysis. SAPPHIRE is a Phase 3 study evaluating sitravatinib plus Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab) versus docetaxel in patients with second or third-line advanced non-squamous non-small cell lung cancer who progressed on prior therapy. The company plans to disclose the study data at a future date. Principal Investigators will be given the option to c
- PR Newswire
Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO®
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial-stage oncology company, today announced that the SAPPHIRE study did not meet its primary endpoint of overall survival at the final analysis. SAPPHIRE is a Phase 3 study evaluating sitravatinib in combination with nivolumab (OPDIVO®)1 versus docetaxel in patients with second or third line advanced non-squamous non-small cell lung cancer (NSQ-NSCLC) who progressed on prior therapy with chemotherapy and immune checkpoint inhibitor therapy. The
Simply Wall St.Growth Investors: Industry Analysts Just Upgraded Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenue Forecasts By 23%
Shareholders in Mirati Therapeutics, Inc. ( NASDAQ:MRTX ) may be thrilled to learn that the analysts have just...
- Simply Wall St.
Mirati Therapeutics First Quarter 2023 Earnings: Beats Expectations
Mirati Therapeutics ( NASDAQ:MRTX ) First Quarter 2023 Results Key Financial Results Revenue: US$7.17m (up by US$6.46m...
ZacksMirati (MRTX) Q1 Earnings & Revenues Beat Estimates, Stock Up
Mirati (MRTX) reports better-than-expected first-quarter results, wherein earnings and revenues beat estimates. The stock climbs 2% on Tuesday. Pipeline development is on track.
- PR Newswire
Mirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Updates
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the first quarter 2023 along with recent pipeline and corporate updates.
- PR Newswire
Mirati Therapeutics and Sarah Cannon Research Institute Announce Strategic, Community Site Focused Partnership to Increase Diversity in Oncology Clinical Studies
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, and Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, today announced a strategic partnership aimed at increasing diversity in clinical study recruitment practices.
- PR Newswire
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 2 new employees with a grant date of May 1, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
PR NewswireMirati Therapeutics to Participate at the Bank of America Securities 2023 Health Care Conference
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Bank of America Securities 2023 Health Care Conference on May 11 at 10:00 a.m. P.T. / 1:00 p.m. E.T. Ben Hickey, chief commercial officer, will represent the company in a fireside chat at the conference.
- PR Newswire
Journal of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data for Adagrasib as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, announced today the Journal of Clinical Oncology published in a Rapid Communication data indicating adagrasib, a potent and selective KRASG12C inhibitor, is well tolerated and demonstrates meaningful clinical activity in patients with pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), and other solid tumors harboring a KRASG12C mutation. Rapid Communications are reserved for publications deemed
- PR Newswire
Mirati Therapeutics® to Report First Quarter 2023 Financial Results and Recent Corporate Updates on May 9, 2023
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will announce financial results for the first quarter 2023 along with recent corporate updates on May 9, 2023. During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on May 9, company executives will provide company updates and review financial results.
- Simply Wall St.
Mirati Therapeutics (NASDAQ:MRTX) shareholders have endured a 57% loss from investing in the stock three years ago
If you love investing in stocks you're bound to buy some losers. Long term Mirati Therapeutics, Inc. ( NASDAQ:MRTX...
- PR Newswire
Mirati To Present Research at the AACR Annual Congress for Two Potentially First-in-Class Clinical Stage Programs
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced a presentation demonstrating in preclinical models the ability of MRTX0902, a selective and potent SOS1 inhibitor, to enhance anti-tumor activity and overcome acquired resistance in combination with either adagrasib, a potent and selective KRASG12C inhibitor, or an epidermal growth factor receptor (EGFR) inhibitor (e.g. osimertinib).
- PR Newswire
Mirati Therapeutics to Participate at the Barclays Global Healthcare Conference
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Barclays Global Healthcare Conference on March 14 at 6:00 a.m. P.T. / 9:00 a.m. E.T. Ben Hickey, chief commercial officer, and Alan Sandler, chief medical officer, will represent the company in a fireside chat at the conference.
- Simply Wall St.
Analyst Forecasts Just Became More Bearish On Mirati Therapeutics, Inc. (NASDAQ:MRTX)
One thing we could say about the analysts on Mirati Therapeutics, Inc. ( NASDAQ:MRTX ) - they aren't optimistic, having...
Insider MonkeyMirati Therapeutics, Inc. (NASDAQ:MRTX) Q4 2022 Earnings Call Transcript
Mirati Therapeutics, Inc. (NASDAQ:MRTX) Q4 2022 Earnings Call Transcript February 28, 2023 Operator: Good afternoon and welcome to the Mirati Therapeutics Fourth Quarter 2022 Earnings Call. My name is Cynthia and I’ll be the operator for today’s call. It is my pleasure to introduce Ryan Asay, Vice President of Corporate Affairs at Mirati. Ryan, you […]
- Simply Wall St.
Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 36% Undervaluation?
Key Insights The projected fair value for Mirati Therapeutics is US$69.74 based on 2 Stage Free Cash Flow to Equity...
ZacksMirati's (MRTX) Q4 Loss Narrows, Krazati Records First Sales
Mirati Therapeutics (MRTX) reports a narrower-than-expected Q4 loss and records first sales of Krazati. Stock rises in after-hours trading.
- PR Newswire
Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the fourth quarter and full year of 2022 along with recent corporate updates.
- PR Newswire
Mirati Therapeutics to Participate at the 43rd Annual Cowen Health Care Conference
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will participate at the 43rd Annual Cowen Health Care Conference on March 6 at 11:10 a.m. P.T. / 2:10 p.m. E.T. David Meek, chief executive officer, will represent the company in a fireside chat.